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Abstract
Bioengineered spider silk is a biomaterial that has exquisite mechanical properties, biocom-
patibility, and biodegradability. Iron oxide nanoparticles can be applied for the detection and
analysis of biomolecules, target drug delivery, as MRI contrast agents and as therapeutic
agents for hyperthermia-based cancer treatments. In this study, we investigated three bio-
engineered silks, MS1, MS2 and EMS2, and their potential to form a composite material
with magnetic iron oxide nanoparticles (IONPs). The presence of IONPs did not impede the
self-assembly properties of MS1, MS2, and EMS2 silks, and spheres formed. The EMS2
spheres had the highest content of IONPs, and the presence of magnetite IONPs in these
carriers was confirmed by several methods such as SEM, EDXS, SQUID, MIP-OES and
zeta potential measurement. The interaction of EMS2 and IONPs did not modify the super-
paramagnetic properties of the IONPs, but it influenced the secondary structure of the
spheres. The composite particles exhibited a more than two-fold higher loading efficiency
for doxorubicin than the plain EMS2 spheres. For both the EMS2 and EMS2/IONP spheres,
the drug revealed a pH-dependent release profile with advantageous kinetics for carriers
made of the composite material. The composite spheres can be potentially applied for a
combined cancer treatment via hyperthermia and drug delivery.
Introduction
Cancer is one of the major causes of death worldwide. Chemotherapy, which is one of the
most common cancer treatments, is often restricted by the resistance of cancer cells to chemo-
therapeutic drugs [1]. Moreover, due to the low efficiency of the targeted delivery, the antican-
cer drugs have toxic side effects by causing damage to healthy tissues. Furthermore, resistance
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to chemotherapeutics or cross-resistance to other drugs can be acquired after cancer therapy,
which can lead to recurrence of the disease [2]. The most common reason for the ineffective-
ness of chemotherapy is drug efflux from cells through transporting protein [3]. One of the
approaches to overcome this phenomenon is extending the blood circulation time of the thera-
peutic agents to allow their accumulation in the target tissue. The results of the recent research
indicated the potential of nanoparticles as a drug delivery platform; they can deposit at the
tumor site and deliver a drug to cancer cells [4–6]. In the most studies, nanoparticle accumula-
tion was due to the enhanced permeability and retention (EPR) effect through the leaky vascu-
lature of tumors and the lack of effective lymphatic drainage [7].
Magnetic nanoparticles are a major class of nanomaterials with great potential in various
diagnostic and therapeutic applications [8]. Iron oxide (Fe3O4) nanoparticles have been inten-
sively investigated as magnetic resonance imaging (MRI) contrast agents and as drug delivery
carriers [9–12]. Moreover, the superparamagnetic property of IONPs enables their application
in hyperthermia treatment [13–15]. Since a temperature above 43˚C induces cell death
through apoptosis and the sensitivity of tumor cells to an increase in temperature is higher
than that of normal cells, hyperthermia therapy can be applied for cancer treatment [16].
Despite the advantages of iron oxide particles, their toxicity and nanotoxicity [17] is one of
the main problems for their in vivo application. The results of several studies showed that the
accumulation of iron ions causes neuronal damage in the brain and inhibits the synthesis of
proteins associated with the growth of neural cells [18, 19]. Therefore, IONPs are being com-
bined with various materials to form non-toxic composites. Khandare et al. demonstrated the
potential of a magnetic composite composed of carbon nanotubes covered with magnetite
nanoparticles, poly(ethylene glycol) (PEG) and fluorophore fluorescein isothiocyanate (FITC)
for cellular imaging [20]. To improve magnetic nanoparticle delivery, polymer-like polylac-
tide-co-glycolide (PLGA) was successfully combined with IONPs [21]. The results of Shi et al.
demonstrated PEGylated fullerene/iron oxide nanocomposites as a promising tool for mela-
noma theranostics applications [22]. Nevertheless, the synthetic polymers may have some limi-
tations, e.g. relatively low biocompatibility, biodegradability, and unfavorable byproducts, thus
naturally derived materials may provide an alternative tool for composite materials produc-
tion. Silks are polymers characterized by the remarkable mechanical properties. Their biocom-
patibility and biodegradability encourage wide biomedical application. Moreover, the recent
development of a bioengineered silk production process solved the problem of spider silk
accessibility [23]. Silk proteins can be processed into various morphological forms such as
fibers, films, hydrogels, scaffolds, micro- and nano-spheres [24]. The potential of silk proteins
to form a platform for chemotherapeutics delivery has been investigated [25]. Both silkworm
silk nanoparticles and spheres made of bioengineered spider silk bind and release various
drugs [5, 26–31]. Moreover, bioengineered spider silk can be functionalized to gain a new
function or modify its properties. For instance, genetic engineering of a silk sequence resulted
in new silk with an opposite charge [32]. Moreover, genetic modification of silk increased the
ability of silk nanoparticles to bind and accumulate inside cells, which improved the efficiency
of drug delivery [5, 33].
Recent studies demonstrated the possibility to combine iron oxide nanoparticles and silk
fibroin into a composite scaffold. Magnetic silk fibroin scaffolds were not toxic and improve
cell adhesion. The scaffolds also exhibited superparamagnetic behavior and excellent hyper-
thermia properties under exposure to an alternating magnetic field [34]. Deng et al. reported
that iron oxide nanoparticles coated with silk fibroin had a higher saturation magnetization
than the previously studied PEG-chitosan/Fe3O4 nanoparticles. The obtained composite parti-
cles also exhibited good neural-cytocompatibility [35]. Microspheres, formed from iron oxide
and silk fibroin, effectively bound and released doxorubicin and selectively accumulated in the
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cytoplasm of cancer cells (HeLa) [4]. However, the presented composite spheres were large
(up to 3000 nm in diameter) with a wide size distribution, which may be a limiting factor for
in vivo applications [4]. Another approach for magnetic silk sphere production was examined
by Chen et al. where the iron oxide/silk fibroin particles with a more uniform size distribution
and mean particle size of 112 nm were prepared by using suspension-enhanced dispersion by
supercritical CO2. This method of sphere production enabled to obtain iron oxide nanoparti-
cles coated with a silk fibroin protein [36].
In this study, we examined three bioengineered spider silk proteins, MS1, MS2, and EMS2.
The proteins were derived from the dragline silk proteins of Nephila clavipes spider MaSp1
(MS1) and MaSp2 (MS2 and EMS2) and differ in their properties due to various amino acid
compositions [30, 31]. These proteins were blended with iron oxide nanoparticle suspensions
and analyzed for their ability to form spheres and bind to IONPs. The EMS2 sphere variant had
the highest affinity for IONPs. We investigated the morphology, size, zeta potential, secondary
structure, iron oxide content, magnetic properties and cytotoxicity of EMS2/IONPs spheres.
Moreover, loading and release studies with chemotherapeutic doxorubicin (Dox) on EMS2/
IONP spheres were performed. The obtained results demonstrated the possibility of forming
composite spheres made of silk and iron oxide nanoparticles that carry and release drugs. Due
to their properties, these particles could have great potential in both magnetic resonance imag-
ing applications and hyperthermia combined with drug delivery therapy against cancer cells.
Materials and methods
Construction, production, and purification of bioengineered silk protein
The construction of expression vectors carrying MS1 [37], MS2 [30] and EMS2 [31] was
described previously. These expression plasmids were transformed into E.coli BLR bacteria
(DE3) (Novagen, Madison, WI) and the large-scale expression was performed using Bioflo
3000 fermentor (New Brunswick Scientific, Edison, NJ) as previously reported [31].
For protein purification, the thermal denaturation method, named 80/20, was used as
described previously [37]. In brief, the bacterial pellet was suspended in a buffer containing 20
mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 100 mM NaCl,
supplemented with Protease Inhibitor Cocktail (2 mM AEBSF, 1 mM phosphoramidon, 130
mM bestatin, 14 mM E-64, 1 mM leupeptin, 0.2 mM aprotinin, and 10 mM pepstatin A;
Sigma, St. Louis, MO) and lysed with 0.2 mg/mL lysozyme (Thermo Fisher Scientific, Inc.,
Waltham,MA). Then, the lysate was sonicated (3 x 10 s), treated with 0.1 mg/mL DNaseI and
100 mM MgCl2 (Sigma, St. Louis, MO) incubated at 4˚C for one h and centrifuged at 20 000 x
g for 30 min at 4˚C. Precipitation of bacterial proteins was performed by heat denaturation
(80˚C) for 20 min. After centrifugation at 20 000 x g for 30 min, silk protein was precipitated
from the supernatant with 20% ammonium sulfate. Subsequently, the silk protein was col-
lected by centrifugation at 10 000 x g for 30 min, rinsed with 20% ammonium sulfate and dis-
solved in 6 M guanidine thiocyanate. The silk solution was dialyzed against 10 mM Tris-HCl
buffer, pH 7.5 using ZelluTrans Dialysis Tubing with an MWCO of 12000−14000 Da (Carl
Roth, Karlsruhe, Germany). The protein was concentrated using Amicon tube filters
MWCO = 10 kDa (Millipore, Jaffrey, NH) and stored at -80˚C until use. The proteins concen-
tration was determined by UV spectroscopy at 280 nm with molar extinction coefficient values
and molecular masses of the proteins as described previously [30, 31].
Iron oxide nanoparticle preparation
A solution of ferric chloride and ferrous chloride (FeCl2 x 4 H2O and FeCl3 x 6 H2O, Sigma,
St. Louis, MO) at a 2:1 molar ratio was prepared in deionized water in a round bottom flask. A
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concentrated ammonia hydroxide solution was added, and the whole solution was stirred for
60 min at 90˚C. The total volume of the mixture was 200 mL. After the system reached a pre-
cipitation state, it was allowed to cool, and the IONPs settled at the bottom of the flask. The
magnetite precipitate was then separated with a neodymium magnet and re-dispersed in fresh
deionized water. The magnetite nanoparticles were washed with distilled water three times
and dried in an oven at 50˚C for 12 h. The dried nanoparticles were re-dispersed in distilled
water. To avoid the formation of both maghemite and hematite, the synthesis was performed
under oxygen-free conditions [38, 39].
Transmission Electron Microscopy (TEM)
The structural characterization was carried out on Philips CM 120kV transmission electron
microscope equipped with a high-resolution pole piece and CCD camera for image registra-
tion at Helmholz Zentrum Berlin. The samples were adsorbed on copper grids covered by
amorphous thin film. After drying, it was deposited in TEM and analyzed in bright as well as
in diffraction mode.
Formation of spider silk/iron oxide spheres
The MS1/IONP, MS2/IONP and EMS2/IONP spheres were produced by salting out with a
potassium phosphate solution. A 50 μL aliquot of silk protein at a concentration of 5 mg/mL
was added to 50 μL of an iron oxide nanoparticle suspension at a concentration of 10 mg/mL,
and then, the solution was rapidly mixed with 1000 μL of 2 M potassium phosphate buffer (pH
of 8) and incubated overnight. Next, the sphere suspension was centrifuged at 10,000 x g for 20
min, and the spheres were rinsed with ultrapure water. The washing was repeated five times.
The MS1/IONP, MS2/IONP and EMS2/IONP spheres suspended in ultrapure water were sub-
sequently sonicated and passed through a PD-10 desalting column (GE Healthcare, Little
Chalfont, UK) to remove unbound iron oxide nanoparticles. Control spheres were produced
by adding 50 μL of the silk protein at a concentration of 5 mg/mL to 50 μL of 10 mM Tris-HCl
(pH of 7.5) and mixing with 1000 μL of 2 M potassium phosphate buffer (pH of 8). To study
the properties of EMS2/IONP, the spheres were formed as follows: 50 μL of silk protein at a
concentration of 2 mg/mL was added to 50 μL of an iron oxide nanoparticle suspension at a
concentration of 10 mg/mL and mixed with 1000 μL of 2 M potassium phosphate buffer at a
pH of 8. Control spheres were prepared as described above using a 50 μL of 10 mM Tris-HCl,
(pH of 7.5) instead of an iron oxide nanoparticle suspension.
Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray
Spectroscopy (EDXS)
The spheres were sonicated for 5 min in an ultrasonic water bath, and 3 μL of the sphere sus-
pension was placed on a cover glass to dry. The samples were subsequently sputtered with an
Au layer using a Quorum Sputter Coater Q150T ES (Quorum Technologies, Ringmer, UK),
and then, the samples were analyzed under a JEOL JSM-7001F (JEOL. Ltd, Tokyo, Japan) field
emission scanning electron microscope at a 15 kV accelerating voltage. Energy-dispersive X-
ray spectroscopy was performed using an X-Max silicon drift detector (Oxford Instruments,
Abingdon, UK) and analyzed using INCA Energy software (Oxford Instruments Analytical,
High Wycombe, UK).
At least 70 individual spheres were measured on several randomly selected SEM images to
calculate an average particle size. The particle sizes were determined with ImageJ 1.46r soft-
ware by measuring the diameter of separated particles. The values represent the mean from
three independent experiments.
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Microwave-Induced Plasma with Optical Emission Spectrometry (MIP–
OES)
The samples were analyzed with a Carl Zeiss Echelle spectrometer (Carl Zeiss AG, Oberko-
chen, Germany) (Model PLASMAQUANT 100) with fiber-optical light-guide, photomulti-
plier tubes (PMTs) and a TE101 microwave plasma cavity. EMS2 and EMS2/IONP spheres
were placed in a quartz vessel and dissolved in 0.5 mL of concentrated HNO3 and 0.5 mL of
30% HCl. Then, the samples were sonicated at 60% of the ultrasonic probe power setting (ca.
40 W) for 120 s and calibrated to 2 mL using volumetric calibrated flasks. Iron concentrations
were analyzed in the continuous mode using an ultrasonic nebulizer (model NOVA-DUO,
Optolab, Warsaw, Poland) equipped with a glass cyclonic spray chamber. The experiments
were repeated three times.
Zeta potential
The zeta potential (ZP) was measured using a Zetasizer Nano Z (Malvern Instruments Ltd,
Worcestershire, UK). The spheres were suspended in 800 μL of water, sonicated for 5 min in
an ultrasonic water bath directly before the measurement and loaded into a capillary cell. The
experiment was repeated three times at room temperature.
Fourier Transform Infrared Spectroscopy (FTIR)
EMS2 and EMS2/IONP spheres were lyophilized, mixed with potassium bromide and then the
blended powder was pressed under pressure to form a tablet-shape pellet. The pellets were ana-
lyzed with a Bruker Equinox 55/S FTIR spectrometer (Bruker Corp, Fremont, CA). Absorp-
tion spectra were obtained from the average of 512 scans with a resolution of 2 cm-1 within a
wavenumber range of 400 to 4000 cm-1. The analysis of spectra was performed with Opus 5.0
software (Bruker Corp. Fremont, CA). The elements of secondary structure were assigned to
the amide I band components: 1605–1615 cm-1 tyrosine side chains, 1616–1637 cm-1 and
1697–1705 cm-1 –beta sheets, 1638–1655 cm-1 random coils, 1665–1662 cm-1 helices, 1663–
1696 cm-1 turns, according to previously described data [40]. The analysis was performed 1, 7
and 14 days after spheres preparation. The experiment was repeated three times.
Superconducting Quantum Interference Device (SQUID)
Zero-field-cooled (ZFC) and field-cooled (FC) magnetization and magnetization loops (M vs.
H) were performed using a SQUID magnetometer MPMS Quantum Design (Quantum
Design International, San Diego, CA). Magnetization loops measurements were carried out at
room temperature and 5 K with a magnetic field in the range of ±50 kOe, which was large
enough to saturate the magnetization. The temperature dependence of the magnetization was
measured at an applied field of 100 Oe between 5 and 350 K.
Doxorubicin loading and release
EMS2 and EMS2/IONP spheres were loaded with doxorubicin (Adriamycin, Pfizer Inc., New
York City, NY) using the post-loading method as described previously [31]. Briefly, 250 μg of
spheres were suspended in 250 μL of PBS, mixed with 50 μL of 2 mg/mL doxorubicin and
incubated overnight with agitation. The spheres were subsequently centrifuged (15 min, 10
000 x g) and the absorbance of the supernatant was measured at 508 nm to define the drug
concentration. The quantification was based on a standard calibration curve of doxorubicin.
The loading efficiency was determined using the equation: loading efficiency (%) = (the
amount of drug loaded) / (amount of drug before loading) x 100%. For release study, the
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spheres were incubated in phosphate buffer solution at pH 7.4, 6 and 4.5 at 37˚C with agita-
tion. The supernatant was collected at indicated time points and replaced with fresh PBS of
proper pH values. The amount of released drug was determined spectrophotometricaly as
described above.
Cytotoxicity
NIH3T3 fibroblasts [31] were cultured in DMEM (Sigma, St. Louis, MO) medium with 10%
fetal bovine serum (PAA Laboratories GmbH, Pasching, Austria) and 80 μg/mL gentamycin
(KRKA, Novo Mesto, Slovenia) at 37˚C in a humidified atmosphere containing 5% CO2. A 2.5
x 104/well of cells were seeded onto 96-well microplate and incubated overnight. The next day
different concentrations of EMS2 and EMS2/IONP spheres were added to cell cultures. After
72 h of incubation 50 μL of 5 mg/mL MTT reagent (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide; Sigma, St. Louis, MO) was added to each well and incubated for 4 h. The
medium was discarded, and purple formazan was dissolved in 200 μL DMSO (dimethylsulfox-
ide; Sigma, St.Louis, MO). The absorbance of the solution was measured at a wavelength of
560 nm using Victor X3 microplate reader (PerkinElmer, Waltham, MA). The experiment was
repeated three times in triplicates.
Statistics
The statistical significance of the differences between the sphere variants was calculated using
analysis of variance (ANOVA). Post hoc tests with the Bonferroni correction were performed.
The differences in the loading efficiency were tested using an unpaired t-test. The differences
between groups were considered significant if the p-value was less than 0.05.
Results and discussion
Iron oxide nanoparticle preparation
Magnetite nanoparticles can be synthesized using various methods, such as ultrasound irradia-
tion [41], sol-gel transformation [42], thermal decomposition [43, 44], or co-precipitation [38].
The most commonly used methods are the last two. Thermal decomposition is based on the
pyrolysis of organic iron precursors, which can be Fe(CO)5 or Fe(acac)3. However, both of
these compounds are toxic and may restrict the medical applications of the obtained magnetite.
The co-precipitation method is characterized by a simple production and implementation and
requires fewer hazardous materials. This method also allows a large number of nanoparticles to
be obtained [9]. Moreover, studies on co-precipitated Fe3O4 nanoparticles have demonstrated
their crystalline nature, which is identical to that of magnetite crystals and superparamagnetic
properties [38, 39].
For this study, the magnetite nanoparticles (Fe3O4) were synthesized using a co-precipita-
tion method [38]. The method was based on the chemical reactions in the overall equation:
2Fe3+ + Fe2+ + 8OH- = Fe3O4 + 4H2O, which was proposed for the mechanism of magnetite
formation. Magnetic particles prepared by the described method were stabilized by charge
(here negatively). The ammonium cation was located in a second shell around the negatively
charged particle surface, thus forming the electrical double layer. The typical TEM image of
the IONPs indicated that the morphology of the nanoparticles was spherical and the crystalline
structure was confirmed (Fig 1). The superparamagnetic nanoparticles were very monodis-
perse (SD < 10%) as shown in the TEM image (Fig 1).
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Production and purification of the bioengineered spider silk proteins MS1,
MS2, EMS2
Three bioengineered spider silks were used in the study: MS1, MS2, and EMS2. The MS1,
MS2, and EMS2 proteins differ in their amino acid sequence, which results in their different
properties such as their hydrophobicity, isoelectric point (pI) and charge at an indicated pH
(summarized in Table 1). These properties can affect the interactions between silk and iron
oxide nanoparticles during the sphere formation process. MS1, MS2, and EMS2 proteins were
produced in E.coli and purified from bacterial cells using a thermal denaturation method as
described previously [5, 30, 31, 37]. The yield of the purification was 1.8, 2 and 3 mg from 1 g
of bacterial pellet for the MS1, MS2, and EMS2 silks, respectively. The purified proteins had
good quality and purity, and no impurities and protein degradation were observed in the
SDS-PAGE gel, what was indicated in our previous studies [30, 31].
Fig 1. TEM characterization of iron oxide nanoparticles. A) TEM image by low magnification with inserted size distribution of IONPs, B) HRTEM image that shows
the ultrastructure and morphology of Fe3O4 nanoparticles.
https://doi.org/10.1371/journal.pone.0219790.g001
Table 1. The properties of the bioengineered spider silk proteins MS1, MS2 and EMS2 predicted on the basis of








Charge at pH 8 (+) (-) (-)
https://doi.org/10.1371/journal.pone.0219790.t001
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Morphology of the spider silk/iron oxide spheres
Spheres were formed upon mixing a high concentration of the potassium phosphate buffer
with a silk solution or with a silk solution and iron oxide nanoparticles. The salting out method
was previously used successfully to produce spheres made of MS1, MS2, EMS2, eADF4(C16)
bioengineered spider silk [45, 46] and silkworm silk fibroin [4, 28]. The eADF4(C16) silk was
based on the dragline silk protein ADF4 from the Araneus diadematus spider [45].
The presence of iron oxide nanoparticles did not impede silk self-assembly to form spheres
(Fig 2). The morphologies of the spheres made of plain silks and silk/iron oxide composites
were different (Fig 2). Moreover, the plain silk spheres presented various morphologies
depending on the protein used (Fig 2A), which was investigated previously [30, 31]. As men-
tioned above, these silks differed in their amino acid sequences, which determine their proper-
ties (Table 1). It was shown previously that the MS2 protein polymerizes more rapidly than
MS1 to form smooth, spherical particles with a lower tendency to aggregate. The morphology
of the MS2 spheres could be a result of a higher β-sheet content than the MS1 spheres [30].
The EMS2 protein was obtained by modifying MS2 by adding a hydrophilic glutamic acid resi-
due to each MS2 repeating unit. The morphologies of the MS2 and EMS2 spheres were differ-
ent, although both types of spheres presented the same secondary structure content.
According to the GRAVY index, EMS2 silk is more hydrophilic than the MS2 protein, which
could result in the different, stickier morphologies of the EMS2 spheres. This phenomenon
might be due to the various assembly processes of these silks [31]. The AFM analysis previously
indicated that both EMS2 and MS2 spheres were round, of smooth surfaces and revealed good
structural integrity, even if they formed clusters [31]. The size and aggregation behavior of silk
spheres is an important aspect of the characteristics of drug carriers and it needs further study.
In the future, the dynamic light scattering (DLS) may introduce important data.
The iron oxide nanoparticles bound to all the MS1, MS2 and EMS2 spheres. MS1/IONP,
MS2/IONP, and EMS2/IONP carriers aggregated more than the plain MS1, MS2, and EMS2
silk spheres, respectively. However, they preserved a spherical morphology (Fig 2). The IONPs
tended to gather in tight clusters and were found on the surface of the spheres in the form of
small bumps, as observed in the SEM image (Fig 2). For the MS1/IONP and MS2/IONP
spheres, the IONPs clusters were located at random areas, whereas the EMS2/IONP spheres
were more uniformly covered with IONPs. The presence of magnetite nanoparticles in the
obtained spheres was confirmed by the elemental analysis using EDXS (Fig 2). The results
showed that the MS1/IONP, MS2/IONP, and EMS2/IONP carriers contained iron oxide
nanoparticles. The highest IONPs content was detected in the EMS2/IONP spheres (Fig 2).
Zhang et al. demonstrated that Fe3O4 and silkworm silk formed composite spheres in the pro-
cess of salting out by using a potassium phosphate buffer [4]. On the surface of these spheres,
aggregates of Fe3O4 nanoparticles were observed with TEM microscopy. It was proposed that
a high concentration of ions (potassium phosphate) can prevent the accumulation of the nega-
tively charged iron oxide nanoparticles inside the obtained carriers [4]. The same could apply
to our EMS2/IONP spheres.
Size of the spider silk/iron oxide spheres
Based on the obtained results, we chose EMS2/IONP composite particles for further detailed
analysis. The size of the nanoparticles used as carriers plays an important role in their pharma-
cokinetics. Larger particles more efficiently activate the human complement system and are
removed more quickly from organisms than their smaller equivalents [47]. We and others
have previously demonstrated the correlation between the initial silk concentration and size of
the formed spheres [28, 31, 48, 49]. Therefore, to obtain smaller and more homogeneous
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particles, we reduced the initial silk concentration before the sphere formation. The spheres
formed by mixing silk at a concentration of 1 mg/mL with a potassium phosphate buffer had a
Fig 2. SEM images and EDXS quantitative results of selected elements of MS1, MS1/IONP spheres, MS2, MS2/IONP spheres, EMS2, and EMS2/IONP spheres.
A) Spheres were prepared by mixing 2 M potassium phosphate at pH 8 with the indicated version of silk (2.5 mg/mL) in the presence or absence of iron oxide
nanoparticles (5 mg/mL). B) EMS2 and EMS2/IONP spheres were formed by mixing 2 M potassium phosphate at pH 8 with a silk solution (1 mg/mL) in the presence
or absence of the iron oxide nanoparticles (5 mg/mL); scale bar– 4 μm.
https://doi.org/10.1371/journal.pone.0219790.g002
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spherical morphology with both EMS2 and EMS2/IONP (Fig 2B). As expected, the spheres
prepared from an initial silk concentration of 2.5 mg/mL were larger than those obtained from
silk at a concentration of 1 mg/mL (Fig 2A vs. 2B). Moreover, we observed a reduction in the
mean size of the spheres that formed in the presence of iron oxide nanoparticles compared
with the spheres made of plain silk (Fig 3A). Furthermore, the EMS2/IONP particles exhibited
a narrower size distribution than the EMS2 spheres (Fig 3B). The decrease in the sphere size
might be due to the higher concentration of the initial solution of silk/iron oxide compared to
that of the plain silk prior to the sphere formation. The studies by Chen et al. demonstrated
that the addition of methotrexate to a silk fibroin solution and Fe3O4 suspension resulted in
the formation of smaller spheres compared with those prepared by mixing silk and iron oxide
nanoparticles [36]. Tu et al. reported that such an observation follows the conventional crystal-
lization theory, which is based on the idea of solution supersaturation levels being a force for
precipitation [50]. Higher concentration solutions can reach supersaturation faster than a less
concentrated solution, which results in an increased nucleation rate, and smaller particles pre-
cipitate from a more concentrated solution [50].
Fig 3. Size analysis of the EMS2 and EMS2/IONP spheres. For the A) size and B) size distribution analyses, the
spheres were prepared by mixing a silk solution (1 mg/mL) and iron oxide nanoparticles (5 mg/mL) with 2 M
potassium phosphate at pH 8. B) Whiskers show the minimal and maximal sizes of the spheres, and the line inside the
box shows the median size. ���indicates statistical significance with p< 0.0001.
https://doi.org/10.1371/journal.pone.0219790.g003
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Secondary structure analysis of plain and composite spheres
The secondary structure composition of the EMS2 and EMS2/IONP spheres was estimated
using the Fourier deconvoluted infrared spectra of the amide I band analysis. The IONPs
caused a significant reduction in the beta-sheet content and an increase in the random coil
and helices contents in the examined spheres (Fig 4A). However, the beta-sheet structures
were dominant in both the EMS2 and EMS2/IONP spheres, which indicated the preservation
of the silk sphere crystalline structure in the presence of magnetite.
The primary amino acid sequence of spider silk proteins is responsible for their
extraordinary physical properties. The stability and strength of silk materials are the result
of the presence of polyalanine motifs (poly(A)), which form beta-sheet structures [51].
Therefore, it is necessary to preserve silk protein secondary structures while combining
them with various compounds to prepare a composite material. The studies of Zhang et al.
observed that both silk fibroin and silk fibroin/iron oxide nanoparticles exhibited mostly
beta-sheet structures, which indicated that the Fe3O4 NPs did not have a major impact on
the silk crystalline structure [4]. Ma et al. showed the negligible influence of PEG and
PLGA compounds on the structural analysis of the silk hydrogel composite [52]. However,
there are examples that the silk secondary structure changed due to the addition of
another element during the formation of a composite material [53]. Feng et al. demon-
strated that a film made of plain silk fibroin consisted mostly of random-coil and alpha-
helix structures, while TiO2/silk fibroin composite films exhibited mostly beta-sheet con-
tent [53].
The structure analysis study was performed at three measurement points, i.e., after 1, 7 and
14 days of storage of the spheres at 4˚C in water. We observed some fluctuations in the content
of the secondary structures of spheres up to the 14th day of storage (some differences were sig-
nificant). From the other hand, previously we analyzed the morphology of plain EMS2 spheres
for six months of storage at 4˚C in water and we did not observe any visible modification in
their spherical morphology [31]. However, these data were qualitative but not quantitative. It
may be interesting to analyze the spheres after a longer period of storage in the terms not only
of the morphology of the spheres but also regarding secondary structure and quantity of
spheres, and, in case of composite spheres, regarding the content of iron oxide. It needs further
evaluation.
Fig 4. Secondary structure analysis of the EMS2 and EMS2/IONP spheres. A) The secondary structure composition of the EMS2 and EMS2/IONP spheres
investigated on the 1st day of storage. B, C) Analysis of the secondary structure composition of the (B) EMS2 and (C) EMS2/IONP spheres during storage on the 1st, 7th
and 14th day. The secondary structure content of both types of particles was calculated after Fourier self-deconvolution of the amide I region of the FTIR spectra. The
mean and error bars indicating the standard deviations are shown. The experiment was repeated three times. � indicates statistical significance with: � p< 0.05; ��
p< 0.01; ��� p< 0.001.
https://doi.org/10.1371/journal.pone.0219790.g004
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Zeta potential of spheres
The zeta potential measurements confirmed the presence of IONPs on the surface of the
EMS2/IONP spheres. Both the EMS2 spheres and IONPs demonstrated negative zeta potential
values (Table 2). However, the presence of magnetite nanoparticles on the sphere surfaces
resulted in a significant reduction in the ZP value (closer to 0 mV) of the EMS2/IONP spheres
(Table 2). Since the IONPs “formed small bumps” and did not evenly cover the entire surface
of the spheres, the ZP value of composite spheres can be an intermediate value between ZP of
IONPs and EMS2 spheres. Based on these data, we concluded that electrostatic interactions
played a minor role in combining silk with IONPs. Previous studies demonstrated the possibil-
ity of binding different components with the same (positive or negative) charge to silk pro-
teins. This phenomenon was observed for positively charged MS1 silk carriers loaded with
positive Dox [5] and positively charged eADF4 silk spheres with positively charged FITC-lyso-
zyme and FITC-BSA [54].
Iron oxide nanoparticle content
EMS2 and EMS2/NP spheres were analyzed to determine the amount of iron nanoparticles.
The microwave-induced plasma with optical emission spectrometry demonstrated the absence
of iron ions in the EMS2 spheres (Table 2). The concentration of iron ions in the sample of
EMS2/IONP spheres was 2.3 μg/mL (+/- 0.16), which after recalculation resulted in 0.029 μg
Fe3+ per 1 μg of spheres (approximately 2.9% IONPs content). This analysis was in agreement
with the results obtained using EDXS (Fig 2).
Magnetic properties of the IONPs and composite spheres
The magnetic properties of the EMS2/IONP spheres were analyzed and compared to those of
the plain magnetite nanoparticles using a superconducting quantum interference device. Fig 5
shows the magnetization curves of the IONPs measured before and after loading on EMS2
spheres. The ZFC curves of all the nanoparticles showed typical peak features at certain tem-
peratures, i.e., the so-called blocking temperature, TB, at 298 K and 262 K for the IONP and
EMS2/IONP samples, respectively. This decrease in TB indicated that the interparticle interac-
tions were weakened in the presence of silk, which was probably due to an increase in the aver-
age distance between the nanoparticle cores. Similar decreases in TB were previously reported
with the increasing interparticle distance, which was accomplished by increasing the particle
concentration in a suspension [55, 56]. The theoretical simulations [57] as well as experimental
studies [58] on superparamagnetic nanoparticles have also shown that the blocking tempera-
ture is proportional to the inverse cube of the interparticle spacing, TB ~ d−3.
Table 2. The iron content and zeta potential of the spheres.
ZP mV [+/- SD] Iron content
(μg Fe/μg spheres)
EMS2 -38.1 [1.1] 0.0
EMS2/IONPs -31.97 [0.6]�� 0.029
IONPs -25.3 [0.9] ND
The spheres were produced by mixing 2 M potassium phosphate at a pH of 8 with silk (1 mg/mL) in the presence or
absence of iron oxide nanoparticles (5 mg/mL). The results of the zeta potential show the mean value and SD of three
experiments in triplicate.
�� indicates statistical significance with p < 0.01
https://doi.org/10.1371/journal.pone.0219790.t002
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Above the blocking temperature, the FC and ZFC curves exhibited similar behaviors, which
indicated the nanoparticles were free to align with the field at high temperature. This state can
be considered superparamagnetic. At low temperatures below the TB, the FC curves decreased
slightly and finally plateaued. A similar behavior was already observed in other systems [58–
61], and in our case, the behavior can be explained considering that magnetite, which was the
main component in the samples, is ferrimagnetic. At low temperatures, ferrimagnetic coupling
within particle cores is stronger than the weak external field and forces the magnetic moments
into the antiparallel or tilted configuration, which reduces the total magnetic moment. At
higher temperatures, the ferrimagnetic coupling weakens, and simultaneously, thermal fluctu-
ations become increasingly significant. Magnetic moments gain more freedom and are more
likely to arrange along the lines of an external magnetic field, which increases the total magne-
tization. At temperatures higher than TB, the thermal fluctuations are large enough to disorder
the system, leading to a reduction in the measured magnetic moment.
Fig 5B shows the hysteresis loops at 5 and 300 K for iron oxide nanoparticles and EMS2/
IONP spheres. Both samples at room temperature showed the expected behavior and did not
display magnetic remanence nor a coercive field. The initial slopes of the magnetization curve
were steep, and the magnetic susceptibility near H = 0 was 9 x 10−2 emu x Oe-1 x g-1 and 2 x
10−2 emu x Oe-1 x g-1 for the IONPs and EMS2/IONP spheres, respectively. At 300 K, the
nanoparticles can be considered superparamagnetic; however, at 5 K, the hysteresis loops for
both samples showed ferromagnetic properties. The coercive field, Hc, in both cases was
Fig 5. Magnetic measurements of the IONPs and silk/ iron oxide spheres (EMS2/IONP). A) Zero-field-cooled
(ZFC) and field-cooled (FC) magnetization curves for IONPs (upper) and EMS2/IONP spheres (bottom); B) Hysteresis
loops at T = 5 and 300 K for IONPs (upper) and EMS2/IONP (bottom) spheres.
https://doi.org/10.1371/journal.pone.0219790.g005
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approximately 330 Oe, while the remanent magnetization, Mr, was approximately 16.3 emu x
g-1 and 2.8 emu x g-1 for the IONPs and EMS2/IONP spheres, respectively. The saturation
magnetization, Ms, at 5 K for the IONP sample was approximately 70 emu x g-1, which was
smaller than that of the bulk magnetite but agreed with the data for magnetite nanoparticles
reported in the literature [60]. The differences may be due to dipolar interactions among the
nanoparticles, different particle sizes or spacings among the particles, or the presence of
admixtures of other iron oxides, such as hematite. The value of the saturation magnetization of
the sample EMS2/IONP was much smaller than that of the IONP sample, and this was a direct
result of the fact that a significant proportion of the sample mass was non-magnetic silk, which
did not add to the magnetic moment.
Drug loading and release
Drug loading was performed using a post-loading method, as described previously.[30] For
both EMS2 and EMS2/IONP spheres, a total of 250 μg of particles was incubated with doxoru-
bicin. The loading efficiency of Dox into the EMS2 spheres was similar to that reported previ-
ously (Fig 6A) [31]. For the EMS2/IONP composite spheres, the loading efficiency of the drug
was more than two times higher than that for the plain EMS2 particles (Fig 6A). Thus, we
observed a higher drug loading efficiency for positively charged doxorubicin on the less nega-
tive EMS2/IONP spheres than on the EMS2 carriers. Various factors could have an impact on
the obtained data. As indicated in Figs 2 and 7, IONPs particles were exposed on the surface of
the sphere in a form of small bumps and they may constitute an additional binding site for the
positively charged drug. Moreover, the difference in the loading efficiency of Dox might be
caused by the difference in the size of the examined particles. The same amount (250 μg) of the
significantly smaller EMS2/IONP spheres resulted in a larger overall particle surface that could
bind more doxorubicin than the EMS2 carriers. Another possibility that needs to be explored
is the analysis of the core of EMS2 and EMS/IONP spheres. Previously we showed the differ-
ence between MS1 and MS2 spheres in terms of their core and content of the secondary struc-
tures [30]. We pointed out the possibility that the looser packing of the MS1 spheres (of
significantly lower beta-sheet content) and their inner pores could enable the penetration of
drug molecules through the sphere and thus contributing to higher Dox uptake than to the
MS2 spheres [30]. From the other hand, the solid, condensed protein core of the MS2 particles
(of significantly higher beta-sheet content) could result in lower diffusion-based loading of
Fig 6. The loading efficiency and release kinetics of doxorubicin (Dox). A) Spheres were loaded with Dox using a post-loading method. B, C) From the B) EMS2 and
C) EMS2/IONP spheres, doxorubicin was released at 37˚C in PBS buffers at pH values of 7.4, 6 and 4.5 over 7 days. The time points for the drug release measurements
were after 1 and 3 h of incubation on day 1 and then every 24 h. The means and standard deviations of three independent experiments are shown. � indicates statistical
significance with p< 0.0001; ��� indicates statistical significance with p< 0.001.
https://doi.org/10.1371/journal.pone.0219790.g006
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doxorubicin [30]. The analysis of the secondary structure content of MS2 and EMS2 spheres
did not indicate the differences between both spheres (approximately 40% of beta-sheet for
both sphere types) [31]. The loading of Dox for MS2 and EMS2 spheres was similar [31]. It
may indicate that the core of MS2 and EMS2 may be similar. Since the beta-sheet content in
EMS2/IONP spheres was significantly less than in EMS2 spheres, the looser packaged silk mol-
ecules could similarly enable more efficiently penetration of doxorubicin. However, this issue
needs further study.
A release study of incorporated doxorubicin was carried out at 37˚C over a period of 7 days
using phosphate buffered saline at pH values of 4.5, 6 and 7.4 (Fig 6B and 6C). For both the
EMS2 and EMS2/IONP spheres, the drug demonstrated a pH-dependent release profile with
the highest and lowest efficiencies at pH values of 4.5 and 7.4, respectively. Fig 7 shows a simi-
lar morphology of the different variants of EMS2/IONP spheres:—plain, loaded with Dox and
after the release of Dox. The highest release of Dox at pH of 4.5 probably neither dependent on
the degradation of spheres nor decomposition of composite spheres. The results in previous
studies revealed that doxorubicin exhibited a pH-dependent release profile from silk fibroin
particles [62] and MS1, MS2 and EMS2 spider silk spheres [5, 30, 31]. One possible explana-
tion of the observed results might be the fact that a lower pH increased the hydrophilicity of
doxorubicin, resulting in a faster release rate from the carriers [63]. The influence of the pH
value on the doxorubicin release profile was reported for the iron oxide/silk fibroin composite
spheres as well [4]. However, these studies did not compare the release kinetics of plain silk
fibroin spheres and silk fibroin/iron oxide composite particles [4]. In this study, we observed
the distinct drug release kinetics from EMS2 and EMS2/IONP spheres (Fig 6B and 6C). The
EMS2/IONP spheres released significantly less Dox at pH values of 6 and 7.4 than the plain
silk spheres and a comparable amount of Dox at a pH of 4.5 (Fig 6B and 6C). This phenome-
non could have a great importance for cancer therapy applications. Our system could enable
effective drug transport in the blood (limited release) to a tumor site (enhanced release).
Cytotoxicity
The MTT cytotoxicity study showed that both the EMS2 and EMS2/IONP spheres were not
toxic (Fig 8). The presence of iron oxide nanoparticles did not cause an increase in the cytotox-
icity of the composite spheres compared to that of the plain silk particles (Fig 8). Similar results
were presented in the studies of Zhang et al. [4]; i.e., the iron oxide/silk fibroin composite
Fig 7. The SEM images of A) EMS2/IONP spheres B) EMS2/IONP spheres loaded with doxorubicin and C) EMS2/IONP spheres after the release
of doxorubicin. EMS2/IONP spheres were prepared by mixing 2 M potassium phosphate at pH 8 with silk (1 mg/mL) and iron oxide nanoparticles (5
mg/mL) and then were loaded with Dox by the post-loading method. Next, Dox was released from EMS2/IONP spheres for 7 days at pH of 4.5; scale
bar– 1 μm.
https://doi.org/10.1371/journal.pone.0219790.g007
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microspheres exhibited no indication of cytotoxicity towards HeLa cells. Thus, the non-cyto-
toxic silk spheres covered with IONPs are promising for in vivo applications.
Conclusions
We investigated a composite material made of bioengineered spider silk and iron oxide nano-
particles. Composite spheres were obtained from MS1, MS2, and EMS2 silk variants, and the
EMS2/IONP spheres were chosen for further investigation because they had the highest IONP
content. The presence of magnetite nanoparticles in the spheres was confirmed using several
methods such as SEM, EDXS, MIP-OES and zeta potential measurements. The addition of
iron oxide nanoparticles influenced the secondary structure of the spheres; however, beta-
sheet structures were dominant in composite particles. Moreover, EMS2/IONP spheres dem-
onstrated good magnetic properties compared to those of the plain magnetite nanoparticles.
Furthermore, the composite spheres exhibited a more than two-fold higher loading efficiency
for doxorubicin than the plain EMS2 particles. A similar release behavior for the drug was
observed from both types of spheres under acidic conditions. However, a slower release was
observed from the composite spheres in a neutral pH compared to that of the plain silk
spheres. It may be important for drug delivery applications because a chemotherapeutic is
released at the tumor site (acidic environment) and not during carrier transport inside the
organism. Moreover, the addition of iron oxide nanoparticles to biocompatible silk did not
result in the cytotoxicity of the obtained spheres. However, the localization of iron oxide nano-
particles on the surface of the spheres could be a drawback for in vivo applications. Further
studies are also required to enhance the number of IONPs that are bound on the surface or
incorporated inside the silk spheres, which may be important for therapeutic use. We also
reported previously that the functionalization of silk with cell binding proteins was necessary
to obtain the internalization of spheres in cells [5]. Another approach that could improve the
Fig 8. Cytotoxicity study by MTT assay. The NIH3T3 fibroblasts were cultured in the presence of EMS2 and EMS2/
IONP spheres for 72 h. Spheres were produced using an initial silk concentration of 1 mg/mL and 2 M potassium
phosphate (pH 8) in the presence or absence of IONPs. The MTT reduction was calculated with reference to the non-
treated cells. Error bars show the standard deviations of the mean of three independent experiments.
https://doi.org/10.1371/journal.pone.0219790.g008
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potential of the composite materials could be blending different silks during the sphere forma-
tion process [64]. This strategy could combine the most favorable properties of the various
silks, which could lead to the formation of more effective tools for cancer therapy.
The results of our study demonstrated the possibility to produce cytocompatible spheres
made of iron oxide/spider silk composite materials with a high magnetism and enhanced
potential for chemotherapeutic drug loading. Such a vehicle can be potentially applied for
magnetic resonance imaging and as a drug carrier for cancer therapy. Moreover, the combined
treatment of hyperthermia and drug delivery may enhance the effectiveness of cancer
treatments.
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